CAR-T Therapy for Pediatric Neuroblastoma: Hope on the Horizon for High-Risk Cases Executive Summary: Key Takeaways Precision Target: The primary target for CAR-T in neuroblastoma is the GD2 antigen, which is highly expressed on tumor cells and minimally present in healthy tissue. The Challenge: High-risk and especially Relapsed or Refractory Neuroblastoma (R/R NB) carry a poor prognosis, where traditional treatments often fail to secure a durable, long-term cure. The Promise: GD2-CAR-T represents a revolutionary approach, being the first cellular immunotherapy designed specifically for pediatric solid tumors. This therapy aims to achieve deep remission and eliminate minimal residual disease (MRD). Breakthrough Potential: CAR-T is projected to significantly increase complete remission rates and offers a potent, later-line treatment that can complement or even surpass current monoclonal antibody therapies. Neuroblastoma is a challenging pediatric cancer, responsible for a disproportionate number of childhood cancer-related deaths. However, advances in cellular immunotherapy are opening new doors.